CD274 and non-small cell lung carcinoma: Results from the phase III PEARLS/KEYNOTE-091 trial have also been reported, showing significant improvement of DFS with adjuvant pembrolizumab compared with placebo in an all-comers population for PD-L1 expression with resected stage IB-IIIA NSCLC (HR 0.81, 95% CI: 0.68–0.96) [22]; the benefit was only observed among those who also received adjuvant chemotherapy.